HealthQuill Pharma
Mpox cases continue to surge and meet the criteria of a public health emergency of international concern, the World Health Organization stated.
Health Medical Pharma

WHO maintains mpox as a public health emergency of global concern

HQ Team June 10, 2025: Mpox cases continue to surge and meet the criteria of a public health emergency of international concern, the.

Read More
Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales threshold of its antifungal therapy in the Asia Pacific region, triggering a milestone payment.
Drugs Health Pharma

Sales surge triggers Pfizer’s $2.5 million milestone payment to Basilea

HQ Team June 5, 2025: Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales.

Read More
Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products for diabetes and other chronic diseases.
Drugs Health Pharma

Lilly, Sweden’s Camurus sign $870 million pact for incretin products

HQ Team June 4, 2025: Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products.

Read More
British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the disease or the patient dying by 56% compared to the usual treatment.
Drugs Health Pharma

AstraZeneca’s pill to treat breast cancer cuts disease worsening by 56%

HQ Team June 4, 2025: British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the.

Read More
A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.
Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer 

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not.

Read More
Billionaire Elon Musk’s Neuralink has raised $650 million in Series E funding from key investors and its clinical trials for brain implant devices have started in three countries.
Drugs Health Pharma

Musk’s Neurolink raises $650 million, brain implant trials start in 3 countries

HQ Team June 3, 2025: Billionaire Elon Musk’s Neuralink has raised $650 million in Series E funding from key investors and its clinical.

Read More
AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by 44% compared to a taxane, trastuzumab and pertuzumab combination. 
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu cuts breast cancer progression by 44%

HQ Team June 3, 2025: AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by.

Read More
The number of active Covid-19 cases in India approached the 4,000-mark, with 161 people being infected with the disease in southern Kerala state and 82 being reported from the capital, New Delhi, as of June 2. 
Drugs Health Pharma

India’s active Covid-19 cases nears 4,000-mark, 32 deaths since January

HQ Team June 3, 2025: The number of active Covid-19 cases in India approached the 4,000-mark, with 161 people infected with the disease.

Read More
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

Read More
US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation of an immunotherapy candidate to treat multiple tumour types.
Drugs Health Pharma

Bristol, BioNTech in $11.1b pact for immunotherapy candidate

HQ Team June 2, 2025: US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation.

Read More